Pfizer and BioNTech Submit Data Backing Vaccine for Children 5 to 11

Health
By BY SHARON LAFRANIERE, SHASHANK BENGALI AND NOAH WEILAND from NYT Health https://ift.tt/3m9YwDo
via IFTTT Children and Childhood, Vaccination and Immunization, Clinical Trials, Coronavirus (2019-nCoV) The companies said that their vaccine was safe and effective in that age group, and that they would submit a formal request in the coming weeks to U.S. regulators to allow a pediatric dose.

Comments

Popular posts from this blog

Should the Autism Spectrum Be Split Apart?

The Young Women Grappling With an ‘Old Man’s Disease’